(Q35909592)

11 August 2017

1 reference

title

Assessment of therapeutic response in patients with metastatic bone disease (English)

1 reference

11 August 2017

5

Mark Clemons

1 reference

11 August 2017

Andrew Clamp

1

1 reference

11 August 2017

Sarah Danson

series ordinal

2

1 reference

11 August 2017

Huy Nguyen

series ordinal

3

1 reference

11 August 2017

David Cole

series ordinal

4

1 reference

11 August 2017

language of work or name

1 reference

1 October 2004

1 reference

Lancet Oncology Commission

11 August 2017

1 reference

11 August 2017

5

1 reference

11 August 2017

10

1 reference

11 August 2017

607-616

1 reference

Prostate carcinoma: defining therapeutic objectives and improving overall outcomes

11 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Risk of complications from bone metastases in breast cancer. implications for management

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

The clinical use of bone resorption markers in patients with malignant bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Healing flare in skeletal metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Primary treatment endpoint following palliative radiotherapy for painful bone metastases: need for a consensus definition?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Dual X-ray absorptiometry detects disease- and treatment-related alterations of bone density in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Monitoring therapeutic response in skeletal metastases using dual-energy x-ray absorptiometry: a prospective feasibility study in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Tumor marker kinetics in the monitoring of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Serum HER-2/neu in the management of breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Clinical review 165: Markers of bone remodeling in metastatic bone disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

The development and function of the skeleton and bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Biochemical prediction of response of bone metastases to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Assessment of response of bone metastases to systemic treatment in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Bone markers in the management of patients with skeletal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Metabolic effects of pamidronate in patients with metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Markers of bone resorption in patients treated with pamidronate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Bone resorption predicts for skeletal complications in metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Urinary carboxyterminal telopeptide of collagen I as a potential marker of bone metastases chemotherapy monitoring in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

Should all breast cancer patients with symptomatic bone metastases be treated with bisphosphonates? The case in support

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901596-7

7 January 2021

10.1016/S1470-2045(04)01596-7

Identifiers

DOI

1 reference

11 August 2017

1 reference